schliessen

Filtern

 

Bibliotheken

Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study

Rheumatic heart disease (RHD) is the principal cause of valvular heart disease–related mortality and morbidity in low- and middle-income countries. The disease predominantly affects children and young adults. It is estimated that RHD may potentially be responsible for 1.4 million deaths annually wor... Full description

Journal Title: American Heart Journal April 2012, Vol.163(4), pp.535-540.e1
Main Author: Karthikeyan, Ganesan
Other Authors: Zühlke, Liesl , Engel, Mark , Rangarajan, Sumathy , Yusuf, Salim , Teo, Koon , Mayosi, Bongani M
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0002-8703 ; E-ISSN: 1097-6744 ; DOI: 10.1016/j.ahj.2012.01.003
Link: https://www.sciencedirect.com/science/article/pii/S0002870312000051
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_ahj_2012_01_003
title: Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study
format: Article
creator:
  • Karthikeyan, Ganesan
  • Zühlke, Liesl
  • Engel, Mark
  • Rangarajan, Sumathy
  • Yusuf, Salim
  • Teo, Koon
  • Mayosi, Bongani M
subjects:
  • Medicine
ispartof: American Heart Journal, April 2012, Vol.163(4), pp.535-540.e1
description: Rheumatic heart disease (RHD) is the principal cause of valvular heart disease–related mortality and morbidity in low- and middle-income countries. The disease predominantly affects children and young adults. It is estimated that RHD may potentially be responsible for 1.4 million deaths annually worldwide and 7.5% of all strokes occurring in developing countries. Despite the staggering global burden, there are no contemporary data documenting the presentation, clinical course, complications, and treatment practices among patients with RHD. The REMEDY study is a prospective, international, multicenter, hospital-based registry planned in 2 phases: the vanguard phase involving centers in Africa and India will enrol 3,000 participants with RHD over a 1-year period. We will document clinical and echocardiographic characteristics of patients at presentation. Over a 2-year follow-up, we will document disease progression and treatment practices with particular reference...
language: eng
source:
identifier: ISSN: 0002-8703 ; E-ISSN: 1097-6744 ; DOI: 10.1016/j.ahj.2012.01.003
fulltext: fulltext
issn:
  • 0002-8703
  • 00028703
  • 1097-6744
  • 10976744
url: Link


@attributes
ID930304790
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_ahj_2012_01_003
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_ahj_2012_01_003
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18ABBQC
19ABFNM
20ABMZM
21ABYKQ
22ACDAQ
23ACRLP
24AEKER
25AEVXI
26AFKWA
27AFTJW
28AFXIZ
29AGHFR
30AGUBO
31AGYEJ
32AHHHB
33AIKHN
34AITUG
35AJBFU
36AJOXV
37AJRQY
38AJUYK
39AMFUW
40ANZVX
41BLXMC
42BNPGV
43EO8
44EO9
45EP2
46EP3
47FDB
48FGOYB
49FIRID
50FNPLU
51G-Q
52GBLVA
53HEB
54HMK
55HMO
56J1W
57KOM
58LCYCR
59OA.
60OAUVE
61OL~
62P-8
63P-9
64PC.
65Q38
66R2-
67RPZ
68SAE
69SDF
70SDG
71SDP
72SEL
73SES
74SEW
75SSH
76SSZ
77T5K
78UV1
79Z5R
80~G-
pqid1504638779
galeid287163549
display
typearticle
titleRationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study
creatorKarthikeyan, Ganesan ; Zühlke, Liesl ; Engel, Mark ; Rangarajan, Sumathy ; Yusuf, Salim ; Teo, Koon ; Mayosi, Bongani M
ispartofAmerican Heart Journal, April 2012, Vol.163(4), pp.535-540.e1
identifier
subjectMedicine
descriptionRheumatic heart disease (RHD) is the principal cause of valvular heart disease–related mortality and morbidity in low- and middle-income countries. The disease predominantly affects children and young adults. It is estimated that RHD may potentially be responsible for 1.4 million deaths annually worldwide and 7.5% of all strokes occurring in developing countries. Despite the staggering global burden, there are no contemporary data documenting the presentation, clinical course, complications, and treatment practices among patients with RHD. The REMEDY study is a prospective, international, multicenter, hospital-based registry planned in 2 phases: the vanguard phase involving centers in Africa and India will enrol 3,000 participants with RHD over a 1-year period. We will document clinical and echocardiographic characteristics of patients at presentation. Over a 2-year follow-up, we will document disease progression and treatment practices with particular reference...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0002870312000051$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Karthikeyan, Ganesan
1Zühlke, Liesl
2Engel, Mark
3Rangarajan, Sumathy
4Yusuf, Salim
5Teo, Koon
6Mayosi, Bongani M
titleRationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study
description

Rheumatic heart disease (RHD) is the principal cause of valvular heart disease–related mortality and morbidity in low- and middle-income countries. The disease predominantly affects children and young adults. It is estimated that RHD may potentially be responsible for 1.4 million deaths annually worldwide and 7.5% of all strokes occurring in developing countries. Despite the staggering global burden, there are no contemporary data documenting the presentation, clinical course, complications, and treatment practices among patients with RHD.

The REMEDY study is a prospective, international, multicenter, hospital-based registry planned in 2 phases: the vanguard phase involving centers in Africa and India will enrol 3,000 participants with RHD over a 1-year period. We will document clinical and echocardiographic characteristics of patients at presentation. Over a 2-year follow-up, we will document disease progression and treatment practices with particular reference...

subjectMedicine
general
0English
1Mosby, Inc
210.1016/j.ahj.2012.01.003
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_ahj_2012_01_003
issn
00002-8703
100028703
21097-6744
310976744
rsrctypearticle
creationdate2012
addtitleAmerican Heart Journal
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41B1
51P~
61RT
71~.
8457
94G.
107-5
118P~
129JM
13AABNK
14AAEDT
15AAKOC
16AAOAW
17AAQFI
18ABBQC
19ABFNM
20ABMZM
21ABYKQ
22ACDAQ
23ACRLP
24AEKER
25AEVXI
26AFKWA
27AFTJW
28AFXIZ
29AGHFR
30AGUBO
31AGYEJ
32AHHHB
33AIKHN
34AITUG
35AJBFU
36AJOXV
37AJRQY
38AJUYK
39AMFUW
40ANZVX
41BLXMC
42BNPGV
43EO8
44EO9
45EP2
46EP3
47FDB
48FGOYB
49FIRID
50FNPLU
51G-Q
52GBLVA
53HEB
54HMK
55HMO
56J1W
57KOM
58LCYCR
59OA.
60OAUVE
61OL~
62P-8
63P-9
64PC.
65Q38
66R2-
67RPZ
68SAE
69SDF
70SDG
71SDP
72SEL
73SES
74SEW
75SSH
76SSZ
77T5K
78UV1
79Z5R
80~G-
startdate20120401
enddate20120431
lsr40American Heart Journal, April 2012, Vol.163 (4), pp.535-540.e1
doi10.1016/j.ahj.2012.01.003
citationpf 535 pt 540.e1 vol 163 issue 4
lsr30VSR-Enriched:[pqid, galeid]
sort
titleRationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study
authorKarthikeyan, Ganesan ; Zühlke, Liesl ; Engel, Mark ; Rangarajan, Sumathy ; Yusuf, Salim ; Teo, Koon ; Mayosi, Bongani M
creationdate20120400
lso0120120400
facets
frbrgroupid6253328866335300563
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Karthikeyan, Ganesan
1Zühlke, Liesl
2Engel, Mark
3Rangarajan, Sumathy
4Yusuf, Salim
5Teo, Koon
6Mayosi, Bongani M
jtitleAmerican Heart Journal
creationdate2012
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Karthikeyan
1Zühlke
2Engel
3Rangarajan
4Yusuf
5Teo
6Mayosi
aufirst
0Ganesan
1Liesl
2Mark
3Sumathy
4Salim
5Koon
6Bongani M
auinitG
auinit1G
au
0Karthikeyan, Ganesan
1Zühlke, Liesl
2Engel, Mark
3Rangarajan, Sumathy
4Yusuf, Salim
5Teo, Koon
6Mayosi, Bongani M
atitleRationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study
jtitleAmerican Heart Journal
risdate201204
volume163
issue4
spage535
epage540.e1
pages535-540.e1
issn0002-8703
eissn1097-6744
formatjournal
genrearticle
ristypeJOUR
abstract

Rheumatic heart disease (RHD) is the principal cause of valvular heart disease–related mortality and morbidity in low- and middle-income countries. The disease predominantly affects children and young adults. It is estimated that RHD may potentially be responsible for 1.4 million deaths annually worldwide and 7.5% of all strokes occurring in developing countries. Despite the staggering global burden, there are no contemporary data documenting the presentation, clinical course, complications, and treatment practices among patients with RHD.

The REMEDY study is a prospective, international, multicenter, hospital-based registry planned in 2 phases: the vanguard phase involving centers in Africa and India will enrol 3,000 participants with RHD over a 1-year period. We will document clinical and echocardiographic characteristics of patients at presentation. Over a 2-year follow-up, we will document disease progression and treatment practices with particular reference...

pubMosby, Inc
doi10.1016/j.ahj.2012.01.003
lad01American Heart Journal
date2012-04